Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri Purchases 10,000 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 25th. The shares were acquired at an average price of $3.20 per share, with a total value of $32,000.00. Following the transaction, the chief executive officer now directly owns 538,260 shares of the company’s stock, valued at approximately $1,722,432. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Abeona Therapeutics Trading Up 5.5 %

Shares of ABEO stock opened at $3.44 on Tuesday. The stock has a market capitalization of $94.10 million, a price-to-earnings ratio of -1.33 and a beta of 1.49. Abeona Therapeutics Inc has a 12-month low of $2.83 and a 12-month high of $9.01. The stock’s 50-day moving average price is $7.23 and its 200-day moving average price is $5.62.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, research analysts predict that Abeona Therapeutics Inc will post -2.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ABEO. Adage Capital Partners GP L.L.C. raised its stake in Abeona Therapeutics by 84.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock valued at $13,682,000 after purchasing an additional 1,488,834 shares in the last quarter. AIGH Capital Management LLC grew its stake in shares of Abeona Therapeutics by 77.7% in the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after buying an additional 496,278 shares in the last quarter. Citigroup Inc. grew its stake in shares of Abeona Therapeutics by 125.0% in the 3rd quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company’s stock worth $1,894,000 after buying an additional 250,000 shares in the last quarter. Barclays PLC grew its stake in shares of Abeona Therapeutics by 100.0% in the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock worth $1,564,000 after buying an additional 185,638 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Abeona Therapeutics in the 3rd quarter worth $648,000. 80.56% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABEO. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, April 23rd.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.